MRI-based Approaches for Multi-parametric Model to Early Predict Pathological Complete Response to Neoadjuvant Therapy in Breast Cancer

Launched by GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL · May 28, 2021

Keywords

ClinConnect Summary

Breast cancer is the most prevalent cancer among women worldwide. NAT has been well established in managing breast cancer for patients with locally advanced cancer and early-stage operable breast cancers of specific molecular subtypes. Though pCR has been demonstrated to be associated with better survival, it can only be judged by pathological testing of surgically resected specimens. Thus, predicting pCR earlier during NAT is imperative and can timely switch to a new personalized treatment strategy and exempt from unnecessary chemotherapy toxicity for patients.

This is a multicenter, pros...

Gender

FEMALE

Eligibility criteria

• 1. For training cohort:
• Inclusion Criteria:
• • Age ≥18 years;
• • Histologically confirmed invasive breast carcinoma;
• • Clinical stage II-III at presentation;
• • Complete basic information and image data;
• • Have MRI imaging data at baseline and after the first cycle of NAC;
• • Finish the standard NAC treatment and undergo surgery;
• Exclusion Criteria:
• • With chemotherapy contraindications;
• • Multifocal of multicentric lesions;
• • Poor quality of MRI images;
• 2. For validation cohort:
• Inclusion Criteria:
• • Age ≥18 years;
• • Complete basic information and image data;
• • Clinical stage II-III at presentation;
• • Scheduled for neoadjuvant chemotherapy;
• • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• • Signed informed consent;
• Exclusion Criteria:
• • With chemotherapy contraindications;
• • Metastatic breast cancer;
• • Multifocal of multicentric lesions;